

**March 2, 2010**

**Medipattern Chosen by Doshi Diagnostic Imaging to Support Total Breast Care Program**

**B-CAD-FOR-LIFE package to be deployed in 38 centers in the United States**

TORONTO, ONTARIO--(Marketwire - March 2, 2010) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, is pleased to announce that it has signed its largest B-CAD-FOR-LIFE(TM) agreement to date with Doshi Diagnostic Imaging Services ("Doshi"). Doshi operates 38 sites with more than 115 sonographers located in both New York and Florida, and plans to deploy the B-CAD-FOR-LIFE package throughout all its locations. Installation has started and will commence based upon a rollout schedule over the next several months.

B-CAD(R) is computer aided detection (CAD) for breast ultrasound imaging. B-CAD can streamline workflow, provide a consistent communication platform, eliminate transcription costs and maintain compliance with the ACR BI-RADS (American College of Radiology - Breast Imaging Reporting and Data System) standards for breast ultrasound. It is an ideal tool for large imaging groups where communication is a key part of an accurate reporting process. Under the B-CAD-FOR-LIFE package all of the separate components that are required to install, train, use and maintain B-CAD are available under one monthly fee.

After decades of delivering exceptional service to its patients, Doshi Diagnostic, the premier radiology provider on the east coast, created "TOTAL BREAST CARE" - a program solely dedicated to improving the delivery of breast care for women. The Center is focused exclusively on breast health by providing the most advanced tools and techniques for the diagnosis and treatment of breast disease and breast cancer. Doshi Diagnostic's Total Breast Care program provides every facet of breast cancer care on-location. This patient-focused, world-class center incorporates every facet of optimal breast health management. To minimize waiting for results, the center strives to provide women with results from their screening examinations and any additional studies needed before they leave the Center.

"We provide the most innovative testing available in the management of breast care, including Digital Mammography, Breast Ultrasound, Breast MRI, Stereotactic Biopsy, Ultrasound-Guided Biopsy, MRI-Guided Biopsy, Pathology, Surgery, and Oncology in a centralized medical center setting. Now, we are pleased to include CAD for breast ultrasound in our TOTAL BREAST CARE package," comments Dr. Leena Doshi, founder and medical director of Doshi Diagnostic Imaging. "DOSHI has grown from my first office in Flushing to be the largest privately owned imaging practice in the United States. We've grown through our active pursuit of quality in patient care, and B-CAD exemplifies our mission. B-CAD improves quality of communication, thoroughness in reporting and enrichment of evidence-based medicine which all

contribute to improved patient care. The B-CAD-FOR-LIFE addresses many of the purchasing decisions facing imaging centers in the U.S. today. This was one of the easiest decisions we've made."

"We welcome Doshi Diagnostic Imaging to the B-CAD family. Doshi's many locations with multiple sonographers communicating to the various radiologists make it an ideal B-CAD customer. Through its innovative screening programs, Doshi touches the lives of over 50,000 women each month, resulting in over 5,000 breast ultrasound exams monthly," stated Jeff Collins, CEO of Medipattern. "With the addition of Doshi, B-CAD-FOR-LIFE will potentially report on over 10,000 breast ultrasound exams per month, a very exciting milestone for this program. We look forward to working with the team at Doshi and congratulate our dealer Physicians Consultant Medical Sales on facilitating this transaction."

About The Medipattern Corporation:

Medipattern(R) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD(R) advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza(TM) CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: [www.medipattern.com](http://www.medipattern.com).

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at [www.sedar.com](http://www.sedar.com)). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

B-CAD(R) and Medipattern(R) are a registered mark of The Medipattern Corporation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.